MWM
NBIX icon

MOKAN Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

MOKAN Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,585
Closed -$604K – 117
2026
Q1 		$604K Buy
4,585
+2,642
+136% +$351K 0.27% 82
2025
Q4 		$276K Buy
1,943
+378
+24% +$54.8K 0.12% 86
2025
Q3 		$220K Buy
+1,565
New +$212K 0.11% 89

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM

MOKAN Wealth Management's NBIX Position: Q2 2026 in Review

MOKAN Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 4,585 shares — an estimated $604K sold.

MOKAN Wealth Management first reported a position in NBIX in Q3 2025 and held it in 3 quarters. The position peaked at $604K in Q1 2026. 264 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • MOKAN Wealth Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • MOKAN Wealth Management sold 4,585 Neurocrine Biosciences shares in Q2 2026, an estimated $604K.
  • MOKAN Wealth Management first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 3 quarters.
  • MOKAN Wealth Management's Neurocrine Biosciences position peaked at $604K in Q1 2026.
  • 264 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on MOKAN Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.